Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs? gan Catherine Y. Lau, Nigel S. B. Rawson

Cael y testun llawn

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices gan David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist

Cael y testun llawn

Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement gan Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski

Cael y testun llawn